This recombinant monoclonal antibody is developed as a research-grade biosimilar to Feladilimab, targeting the Inducible T-cell CO-Stimulator (ICOS), a critical immune checkpoint receptor expressed on activated T cells. ICOS plays a pivotal role in T-cell activation, differentiation, and effector function by delivering co-stimulatory signals following antigen recognition. Upon binding to its ligand ICOSL, ICOS promotes the expansion and function of various T-cell subsets, including follicular helper T cells and regulatory T cells, making it essential for adaptive immune responses. Dysregulation of ICOS signaling has been implicated in autoimmune diseases, transplant rejection, and represents an emerging target in immuno-oncology research.
Feladilimab is an investigational agonistic antibody designed to enhance anti-tumor immunity by stimulating ICOS-mediated T-cell responses. This biosimilar provides researchers with a valuable tool for investigating ICOS biology, exploring combination immunotherapy strategies, and studying T-cell co-stimulation mechanisms in various disease models. It enables detailed examination of ICOS pathway modulation in preclinical studies and supports the development of novel therapeutic approaches targeting immune checkpoint pathways.
Email: support@cusabio.com
Distributors Worldwide